Rezolute (RZLT) Stock Price
Rezolute Price
The consensus 12-month price target for Rezolute is 6.00 USD, about 56.3% above where the stock trades today. Of 16 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 174% above its 52-week low.
Rezolute stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Rezolute over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Rezolute stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Rezolute's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Rezolute Price |
|---|---|
| 9/18/2026 | 3.84 USD |
| 9/17/2026 | 3.95 USD |
| 9/16/2026 | 4.11 USD |
| 9/15/2026 | 4.14 USD |
| 9/14/2026 | 4.25 USD |
| 9/13/2026 | 4.26 USD |
| 9/11/2026 | 4.18 USD |
| 9/10/2026 | 4.17 USD |
| 9/9/2026 | 4.06 USD |
| 9/8/2026 | 4.51 USD |
| 9/4/2026 | 4.58 USD |
| 9/3/2026 | 4.54 USD |
| 9/2/2026 | 4.56 USD |
| 9/1/2026 | 4.50 USD |
| 8/31/2026 | 4.69 USD |
| 8/30/2026 | 4.67 USD |
| 8/28/2026 | 4.72 USD |
| 8/27/2026 | 5.03 USD |
| 8/26/2026 | 5.04 USD |
| 8/25/2026 | 5.01 USD |
| 8/24/2026 | 4.95 USD |
| 8/21/2026 | 5.09 USD |
| 8/20/2026 | 4.66 USD |
| 8/19/2026 | 4.66 USD |
| 8/18/2026 | 4.66 USD |
| 8/14/2026 | 4.60 USD |
| 8/13/2026 | 4.60 USD |
| 8/12/2026 | 4.72 USD |
| 8/10/2026 | 4.68 USD |
| 8/7/2026 | 4.69 USD |
Rezolute Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Rezolute Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | 2.00 | 66.00 | 191.00 | 400.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 3,200.00 | 189.39 | 109.42 |
| – | – | – | – | – | – | – | – | – | – | – | – | -600.00 | -18.18 | -6.28 | -3.00 |
| -5.00 | -8.00 | -12.00 | -12.00 | -12.00 | -12.00 | -12.00 | -12.00 | -12.00 | -12.00 | -12.00 | -12.00 | -12.00 | -12.00 | -12.00 | -12.00 |
| -10.00 | -14.00 | -20.00 | -26.00 | -25.00 | -20.00 | -22.00 | -41.00 | -55.00 | -70.00 | -79.00 | -52.00 | -23.00 | -36.00 | 102.00 | 164.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | -1,150.00 | -54.55 | 53.40 | 41.00 |
| -11.00 | -14.00 | -20.00 | -29.00 | -30.00 | -20.00 | -20.00 | -41.00 | -51.00 | -68.00 | -74.00 | -53.00 | -23.00 | -24.00 | -11.00 | 130.00 |
| 22.22 | 27.27 | 42.86 | 45.00 | 3.45 | -33.33 | – | 105.00 | 24.39 | 33.33 | 8.82 | -28.38 | -56.60 | 4.35 | -54.17 | -1,281.82 |
| 0.49 | 0.82 | 1.08 | 1.24 | 5.87 | 8.05 | 15.68 | 51.41 | 51.41 | 69.94 | 103.69 | 103.69 | 103.69 | 103.69 | 103.69 | 103.69 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Rezolute generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Rezolute retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Rezolute's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Rezolute has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Rezolute's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Rezolute stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Rezolute Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Rezolute business model & stock analysis
Rezolute SWOT Analysis
Strengths
Rezolute Inc has a strong and experienced management team that brings expertise in the biopharmaceutical industry.
The company has a diverse product pipeline, with several candidates in different stages of development, which provides potential for future growth.
Weaknesses
Rezolute Inc operates in a highly competitive industry, facing competition from established players with greater resources.
The company is relatively smaller in size and has limited financial resources, which may restrict its ability to fully execute on its pipeline.
Opportunities
The increasing demand for innovative therapeutic solutions presents an opportunity for Rezolute Inc to capture market share with its unique products in development.
Strategic partnerships and collaborations can provide access to additional resources, expertise, and potentially accelerate development and commercialization.
Threats
Regulatory challenges and the lengthy approval process pose a threat, potentially delaying market entry and putting pressure on financial resources.
The uncertainty surrounding healthcare policies and reimbursement systems can impact market access and pricing for Rezolute Inc's products.
Rezolute Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Rezolute Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Rezolute historical P/E ratio, EBIT multiple, and P/S ratio
Rezolute annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Rezolute's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Rezolute's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Rezolute's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Rezolute shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Rezolute stock splits
Since 2013, a total of 0.02 shares have been converted from one Rezolute share.
Current Rezolute forecasts and price targets in September 2026
Analyst Price Targets 2026Rezolute Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 6/15/2026 | Maintained | Buy | 39 | |
| 6/3/2026 | Maintained | Outperform | 52 | |
| 6/3/2026 | Maintained | Buy | – | |
| 6/3/2026 | Upgrade | Market PerformMarket Outperform | – | |
| 6/2/2026 | Maintained | Buy | – | |
| 6/2/2026 | Maintained | Buy | 49 | |
| 5/14/2026 | Maintained | Buy | – | |
| 3/25/2026 | Upgrade | NeutralOutperform | 52 | |
| 1/8/2026 | Maintained | Neutral | 52 | |
| 1/8/2026 | Maintained | Buy | 49 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Rezolute Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/5/2026 | -0.15USD | - | 1.12 MUSD | - | 2026 Q3 |
| 9/16/2026 | -0.14USD | -0.26USD | -USD | - | 2026 Q2 |
| 5/12/2026 | -0.14USD | -0.16USD | -USD | - | 2026 Q1 |
| 2/12/2026 | -0.16USD | -0.22USD | -USD | - | 2025 Q4 |
| 11/6/2025 | -0.27USD | -0.18USD | -USD | - | 2025 Q3 |
| 2/12/2025 | -0.33USD | -0.22USD | -USD | - | 2024 Q4 |
| 11/7/2024 | -0.35USD | -0.22USD | -USD | - | 2024 Q3 |
| 5/15/2024 | -0.34USD | -0.34USD | -USD | - | 2024 Q1 |
| 2/13/2024 | -0.27USD | -0.27USD | -USD | - | 2023 Q4 |
| 11/13/2023 | -0.33USD | -0.28USD | -USD | - | 2023 Q3 |
Rezolute shareholder structure
| % | Name |
|---|---|
18.46690% | |
16.41880% | |
11.08350% | |
6.40795% | |
5.29292% | |
4.90917% |
Rezolute Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
50.00% | SEC ↗ | |
31.10% | SEC ↗ | |
22.20% | SEC ↗ | |
22.20% | SEC ↗ | |
22.20% | SEC ↗ | |
21.90% | SEC ↗ | |
20.66% | SEC ↗ | |
20.66% | SEC ↗ | |
20.66% | SEC ↗ | |
20.66% | SEC ↗ |
Rezolute Executives and Management Board
10 members · avg. age 57 · 10 % women
Mr. Nevan Elam (57)
Acting Chairman of the Board, Chief Executive Officer · since 2013
1.19 M USD
Management
Dr. Brian Roberts (50)
Chief Medical Officer
Mr. Daron Evans (51)
Chief Financial Officer
Dr. Sunil Karnawat (58)
Chief Commercial Officer
Board of Directors
Dr. Wladimir Hogenhuis (60)
Independent Director
Mr. Gilbert Labrucherie (53)
Independent Director
Mr. Philippe Fauchet (67)
Independent Director
Dr. Nerissa Kreher (52)
Independent Director
Mr. Young-Jin Kim (67)
Director · since 2019
Mr. Erik Harris (55)
Independent Director
Frequently asked questions about Rezolute
The business model of Rezolute Inc. revolves around developing and commercializing innovative therapies for people with rare and severe chronic disorders. Rezolute focuses on delivering transformative treatments by leveraging their expertise in protein engineering and drug development. The company aims to address unmet medical needs through the discovery, development, and successful commercialization of therapies. Rezolute Inc. utilizes strategic collaborations, licensing agreements, and partnerships to further advance their product portfolio and accelerate their development timelines, delivering potential value to patients, healthcare providers, and shareholders.
Rezolute Inc is primarily active in the pharmaceutical industry.
The main competitors of Rezolute Inc in the market include companies such as Eli Lilly and Company, Novo Nordisk A/S, Sanofi S.A., and Pfizer Inc. These companies also operate in the pharmaceutical and biotechnology industry, focusing on the development and commercialization of innovative therapies. Rezolute Inc competes with these industry leaders by offering its unique portfolio of products and striving to provide effective solutions to patients in need.
Rezolute Inc is a pharmaceutical company founded in 2010. It focuses on the development of therapeutics for chronic diseases like diabetes and rare genetic disorders. Rezolute is committed to providing innovative and effective solutions to improve patient outcomes in these areas. With a dedicated team of experts, the company utilizes cutting-edge technologies to advance its pipeline of drug candidates. Rezolute's history is marked by strategic collaborations and partnerships with leading industry players, reinforcing its position as a promising player in the biopharmaceutical sector. Through its continuous efforts, Rezolute aims to make a significant impact on the lives of patients worldwide.
Rezolute Inc has achieved several significant milestones in its operations. One notable achievement is the successful completion of its Phase 1 clinical trial for its lead candidate, RZ358, in patients with congenital hyperinsulinism (CHI). This milestone demonstrated the safety and tolerability of RZ358 and its potential to treat CHI, a rare genetic disorder. Additionally, the company has obtained orphan drug designation from the FDA for RZ358, providing it with exclusive market rights and potential financial incentives. Rezolute Inc has also entered into strategic partnerships and collaborations with renowned institutions, accelerating the development and commercialization of its innovative therapeutics.
Rezolute Inc primarily operates in the United States.
Rezolute Inc represents values such as innovation, dedication, and integrity. The company focuses on developing novel therapies and solutions for patients with chronic and rare diseases. Rezolute Inc's corporate philosophy is centered around prioritizing patient well-being and improving their quality of life through cutting-edge research and development. With a strong emphasis on scientific excellence and collaboration, Rezolute Inc strives to provide groundbreaking medical solutions that address unmet medical needs.
Analysts currently set an average price target of 8.67 USD for the Rezolute stock (median: 6.00 USD), implying +126.7 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the Rezolute stock: 13 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Rezolute to generate revenue of 385,714.00 USD and earnings per share of -0.51 USD.
Converted at the current exchange rate, the Rezolute share trades at 3.35 EUR (3.84 USD).
The Rezolute share (RZLT) is listed on 1 stock exchanges, including: NASDAQ (RZLT).
The company Rezolute Inc is a US-based biopharmaceutical company that focuses on the discovery and development of new therapeutics for rare endocrine and metabolic disorders. The business model of Rezolute Inc is based on deep biological and medical expertise, high standards for clinical development, and efficient project management to bring new biopharmaceutical products to the market. Rezolute Inc has two main divisions that focus on the discovery and development of drugs suitable for rare endocrine and metabolic disorders. The first division is engaged in the development of peptide and monoclonal antibody drugs for the treatment of congenital hyperinsulinism, diabetes mellitus, and other insulin-resistant diseases. The second division focuses on the discovery and development of drugs for the treatment of rare metabolic diseases such as lysosomal storage diseases, cellular metabolic disorders, and mitochondrial diseases. Rezolute Inc aims to improve the quality of life for patients with rare diseases. To achieve this, the company develops new compounds and products that provide effective and safe therapies for these diseases. Rezolute Inc utilizes a combination of traditional and innovative technologies to maximize the efficacy and safety of new therapeutics. The company works closely with regulatory authorities to obtain approval for new drugs and make them accessible worldwide. Rezolute Inc has several products in the pipeline that are expected to be released soon. These include RZ358, an oral drug for the treatment of congenital hyperinsulinism, and RZ402, an oral drug for the treatment of metabolic disorders. Additionally, the company is working on the clinical development of RZ358 for the treatment of diabetes mellitus, a chronic metabolic disorder that affects millions of people worldwide. In addition to its development activities, Rezolute Inc conducts extensive research and development to identify and develop innovative therapeutic technologies. The company has formed partnerships with academic research institutions, hospitals, and pharmaceutical companies around the world to expand its knowledge and expertise in this area. In summary, Rezolute Inc is a biopharmaceutical company dedicated to the development of therapies for rare endocrine and metabolic disorders. The company uses a combination of traditional and innovative technologies and has an extensive product pipeline tailored to the needs of patients. Rezolute Inc works closely with regulatory authorities to obtain approval for new drugs and make them accessible worldwide.
The expected revenue of Rezolute is 385,714.00 USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Rezolute is -53.19 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Rezolute is currently -7.49. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Rezolute stock.
The price-to-sales ratio (P/S) of Rezolute is currently 1,032.26. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Rezolute stock.
The Eulerpool Quality Score for Rezolute is 2/10.
The ISIN of Rezolute is US76200L3096. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Rezolute is RZLT. The ticker symbol is used to trade Rezolute shares on the stock exchange.
Rezolute paid dividends every year for the past 0 years.
Rezolute is assigned to the 'Health' sector.
The dividends of Rezolute are distributed in USD.
Rezolute stock
Rezolute Peer Group
Rezolute Ticker
Rezolute FIGI
All fundamentals and in-depth analysis of Rezolute
Our stock analysis for Rezolute stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rezolute. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.